Clinical Report: Targeting Mitochondrial Dysfunction in Heart Failure
Overview
This meta-analysis evaluates the efficacy of mitochondrial-targeted agents in heart failure (HF) patients, revealing improvements in left ventricular ejection fraction (LVEF), NYHA class, and reductions in all-cause mortality and HF-related hospitalizations. However, the evidence quality is low due to high risk of bias and substantial heterogeneity.
Background
Mitochondrial dysfunction is a critical factor in the pathophysiology of heart failure, leading to oxidative stress and impaired energy production in cardiomyocytes. Understanding the therapeutic potential of agents targeting mitochondrial function is essential. This review aims to clarify the clinical outcomes associated with such interventions.
Data Highlights
Outcome
Effect Size
Confidence Interval
p-value
LVEF Improvement
SMD: 0.53
95% CI: 0.42–0.65
p < 0.00001
NYHA Class Reduction
RR: 2.38
95% CI: 1.48–3.84
p = 0.0004
All-Cause Mortality Reduction
RR: 0.62
95% CI: 0.47–0.82
p = 0.0007
HF-Related Hospitalizations Reduction
RR: 0.60
95% CI: 0.42–0.85
p = 0.004
Key Findings
Mitochondrial-targeted agents improved LVEF compared to baseline and control groups.
Interventions reduced NYHA functional class.
All-cause mortality was reduced with mitochondrial-targeted therapies.
HF-related hospitalizations were decreased.
The certainty of evidence for these outcomes was rated low due to high risk of bias.
Clinical Implications
The low quality of evidence necessitates caution in the application of mitochondrial-targeted therapies. Further high-quality trials are essential to establish definitive clinical recommendations.
Conclusion
Current evidence regarding mitochondrial dysfunction as a therapeutic target in heart failure is insufficient to warrant widespread clinical adoption of these agents without further validation.
